|Treating rheumatoid arthritis to target: recommendations of an international task force|
JS Smolen, D Aletaha, JWJ Bijlsma, FC Breedveld, D Boumpas, ...
Annals of the rheumatic diseases 69 (4), 631-637, 2010
|EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs|
JS Smolen, R Landewé, FC Breedveld, M Dougados, P Emery, ...
Annals of the rheumatic diseases 69 (6), 964-975, 2010
|EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update|
JS Smolen, R Landewé, J Bijlsma, G Burmester, K Chatzidionysiou, ...
Annals of the rheumatic diseases 76 (6), 960-977, 2017
|American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials|
DT Felson, JS Smolen, G Wells, B Zhang, LHD Van Tuyl, J Funovits, ...
Arthritis & Rheumatism 63 (3), 573-586, 2011
|Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active‐surveillance report|
JJ Gómez‐Reino, L Carmona, VR Valverde, EM Mola, MD Montero
Arthritis & Rheumatism: Official Journal of the American College of …, 2003
|Interleukin‐6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease‐modifying antirheumatic drugs: the …|
MC Genovese, JD McKay, EL Nasonov, EF Mysler, NA da Silva, ...
Arthritis & Rheumatism: Official Journal of the American College of …, 2008
|Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis|
W Hueber, DD Patel, T Dryja, AM Wright, I Koroleva, G Bruin, C Antoni, ...
Science translational medicine 2 (52), 52ra72-52ra72, 2010
|Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force|
JS Smolen, FC Breedveld, GR Burmester, V Bykerk, M Dougados, ...
Annals of the rheumatic diseases 75 (1), 3-15, 2016
|Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study|
G Jones, A Sebba, J Gu, MB Lowenstein, A Calvo, JJ Gomez-Reino, ...
Annals of the rheumatic diseases 69 (01), 88-96, 2010
|Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists|
L Carmona, JJ Gómez‐Reino, V Rodríguez‐Valverde, D Montero, ...
Arthritis & Rheumatism 52 (6), 1766-1772, 2005
|Adipokines as emerging mediators of immune response and inflammation|
F Lago, C Dieguez, J Gómez-Reino, O Gualillo
Nature clinical practice Rheumatology 3 (12), 716-724, 2007
|Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty‐four–week efficacy and safety …|
A Kavanaugh, I McInnes, P Mease, GG Krueger, D Gladman, ...
Arthritis & Rheumatism: Official Journal of the American College of …, 2009
|Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis|
M Otero, R Lago, R Gomez, F Lago, C Dieguez, JJ Gomez-Reino, ...
Annals of the rheumatic diseases 65 (9), 1198-1201, 2006
|Leptin, from fat to inflammation: old questions and new insights|
M Otero, R Lago, F Lago, FF Casanueva, C Dieguez, JJ Gómez-Reino, ...
FEBS letters 579 (2), 295-301, 2005
|Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection|
JJ Gómez‐Reino, L Carmona, M Ángel Descalzo
Arthritis Care & Research: Official Journal of the American College of …, 2007
|The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement|
I Solovic, M Sester, JJ Gomez-Reino, HL Rieder, S Ehlers, HJ Milburn, ...
European Respiratory Journal 36 (5), 1185-1206, 2010
|The emerging role of adipokines as mediators of inflammation and immune responses|
F Lago, C Dieguez, J Gómez-Reino, O Gualillo
Cytokine & growth factor reviews 18 (3-4), 313-325, 2007
|Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor|
A Kavanaugh, PJ Mease, JJ Gomez-Reino, AO Adebajo, J Wollenhaupt, ...
Annals of the rheumatic diseases 73 (6), 1020-1026, 2014
|Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors|
R Westhovens, M Robles, AC Ximenes, S Nayiager, J Wollenhaupt, ...
Annals of the rheumatic diseases 68 (12), 1870-1877, 2009
|Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations|
D Aletaha, R Landewe, T Karonitsch, J Bathon, M Boers, C Bombardier, ...
Arthritis Care & Research: Official Journal of the American College of …, 2008